Table 2 Clinical characteristics of patients who did or did not receive antiplatelet agents
Antiplatelet group | Non-antiplatelet group | p value | |
|---|---|---|---|
Number | 31 | 28 | |
Age | 73 (68–78) | 71 (58.5–80) | 0.27 |
Older age (%) | 54.8 | 42.9 | 0.44 |
Sex (male, %) | 80.7 | 64.3 | 0.22 |
Etiology of ESRD (%) | |||
DN | 48.4 | 32.1 | 0.20 |
NS | 25.8 | 21.4 | 0.69 |
CGN | 9.7 | 21.4 | 0.21 |
ADPKD | 3.2 | 0 | 0.34 |
IgAN | 6.5 | 3.6 | 0.62 |
Other or unknown | 6.5 | 21.4 | 0.093 |
Smoking history (%) | 80.7 | 46.4 | 0.008 |
DM (%) | 61.3 | 53.6 | 0.60 |
Dyslipidemia (%) | 74.2 | 39.3 | 0.009 |
CVD (%) | 80.7 | 25.0 | < 0.001 |
IHD | 58.1 | 10.7 | < 0.001 |
CHF | 16.1 | 10.7 | 0.54 |
Stroke | 22.6 | 0 | 0.007 |
PAD (%) | 22.6 | 3.6 | 0.55 |
RASI (%) | 45.2 | 60.7 | 0.30 |
Statin (%) | 29.0 | 75.0 | < 0.001 |
Warfarin (%) | 6.5 | 10.7 | 0.67 |
ESA | |||
Epoetin α or β (IU/week) | 3750.0 ± 1068.5 | 2750.0 ± 975.4 | 0.51 |
Darbepoetin α (μg/week) | 33.1 ± 9.7 | 47.4 ± 9.4 | 0.29 |
CERA (μg/2 week) | 50 | 75 | – |
Hb (g/dl) | 10.6 ± 0.3 | 10.1 ± 0.29 | 0.28 |
Platelet (× 103/μl) | 19.8 ± 1.2 | 17.9 ± 1.3 | 0.28 |
PT-INR | 1.0 ± 0.1 | 1.1 ± 0.1 | 0.50 |
CRP (mg/dl) | 0.6 ± 0.3 | 0.8 ± 0.3 | 0.71 |
Dialysis duration (month) | 31.8 ± 33.2 | 20.8 ± 27.0 | 0.42 |
AVF anastomosis type (%) | |||
Radiocephalic | 71.0 | 92.9 | 0.031 |
Brachiocephalic | 25.8 | 7.1 | 0.056 |
Radiobasilic | 3.2 | 0 | 0.34 |
Quantity of blood flow (ml/min) | 194.1 ± 6.5 | 190 ± 7.6 | 0.69 |
Flow volume (ml/min) | |||
Before VAIVT | 461.8 ± 86.1 | 373.1 ± 88.5 | 0.47 |
After VAIVT | 816.2 ± 172.9 | 872.1 ± 177.9 | 0.82 |
VAF | |||
Thrombosis (%) | 19.4 | 10.7 | 0.48 |
Adverse event (%) | |||
Serious bleeding event | |||
Intracranial | 0 | 0 | – |
Gastrointestinal | 0 | 0 | – |
CVD event after VAIVT | |||
IHD | 19.4 | 3.6 | 0.061 |
CHF | 6.5 | 3.6 | 0.62 |
Stroke | 3.2 | 0 | 0.34 |